Trials / Completed
CompletedNCT04641312
A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 in Healthy Participants and in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 in healthy participants and participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study has two parts (part A and B). Each part will last up to 10 weeks and may include up to either 13 (part A) or 19 (part B) visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3457263 | Administered SC |
| DRUG | Dulaglutide | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2020-11-25
- Primary completion
- 2021-12-21
- Completion
- 2021-12-21
- First posted
- 2020-11-23
- Last updated
- 2022-01-11
Locations
2 sites across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04641312. Inclusion in this directory is not an endorsement.